Drug Profile
Research programme: anti-tissue factor monoclonal antibodies - Centocor
Alternative Names: Anti-tissue factor monoclonal antibodies - Centocor; CNTO-859; Tissue factor monoclonal antibodies - CentocorLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Centocor
- Class Monoclonal antibodies
- Mechanism of Action Thromboplastin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours in USA
- 03 Mar 2008 Preclinical development is ongoing
- 07 Dec 2005 Data presented at the 17th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2005) have been added to the Cancer pharmacodynamics section